Taking peoplePhase 1
Tests IEV407 alone or with endocrine therapy in advanced breast cancer
Tests IEV407, alone or with endocrine therapy, in adults with advanced breast cancer.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Ancona, ItalySee the siteAlso in 4 other countries, 7 sites
- Trial code
- EU 2025-522707-26-00
- U1111-1332-7380
- Registry title
- A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 40 people, planned
- Started
- 30 Sept 2026
- Expected to end
- 8 Jun 2032
- Type of study
- Interventional
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced breast cancer of the HR+/HER- type. IEV407 is given alone or together with endocrine therapy.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Advanced HR+/HER- breast cancer
Where in Italy
Also in 4 other countries, 7 sites
- Azienda Ospedaliero-Universitaria delle MarcheAncona, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests IEV407 alone or with endocrine therapy in advanced breast cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 21 October 2026